Pathos pursuing biotech upside

This reveals that Pathos is trying to capture biotech upside, not just software revenue. ConcertAI sells tools and data to pharma teams that still choose the drug, write the protocol, and own the trial economics. Pathos uses a similar data and modeling stack to pick programs itself, buy or incubate assets, and run trials with its own operating team, which turns the platform from vendor infrastructure into a drug creation engine.

• ConcertAI packages its oncology data and AI into sponsor workflows like site selection, trial matching, and patient insight products built on CancerLinQ, a classic B2B model where the customer pays for better trial execution but keeps the asset value.
  2 concertai
• Pathos is built to own that asset value. Its platform says it simulates thousands of trial scenarios, identifies likely responder populations, and supports small internal teams running studies. The DeuterOncology deal shows this is already being used to acquire and advance in house programs.
  1 sacra 3 pathos 4 pathos
• Owkin sits closer to Pathos than ConcertAI does, but from a different starting point. Owkin emphasizes federated access across hospital partners and sells data, biomarkers, and trial support from that network, while also running its own clinical programs. Pathos is more tightly organized around internal program origination and execution.
  5 owkin 6 owkin 7 owkin

The next step is a split between AI for pharma and AI as pharma. Vendors like ConcertAI can become embedded trial software and data layers across many sponsors. Companies like Pathos and Owkin are pushing further, using the same stack to decide which drugs to back and to run those programs themselves, where the payoff is much larger.